I promise

"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Wednesday, February 26, 2014

My Story of Triple Negative Breast Cancer Day in Toledo at UTMC on 3.3.14

Public invited to learn about aggressive subtype of breast cancer; RSVP by Feb. 28


The most successful breast cancer treatments target three receptors, but what happens when none of these receptors are present?
triple negative breast cancer logo with dateThat’s the case in patients who are diagnosed with triple negative breast cancer, a rare and sometimes aggressive subtype of breast cancer. Their condition is the focus of a new public outreach effort.
The University of Toledo Medical Center will host “A Different Shade of Pink” Monday, March 3, from 5:30 to 8 p.m. in recognition of Triple Negative Breast Cancer Day to educate the public about the disease. The event will be held at the Eleanor N. Dana Cancer Center.
Triple negative breast cancer occurs when estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 — the three receptors known to fuel breast cancer — aren’t present.
Because only 15 of every 100 breast cancer diagnoses are triple negative, many are unaware of what the disease entails and what options are available for treatment. The disease also is often hard to diagnose because it is more common in younger women and is not always detected in mammograms.
“I had a friend pass away from triple negative breast cancer a year ago at age 26,” said Melissa Paskvan, UT Medical Center patient who was diagnosed with this type of breast cancer in 2009 and has been in remission for four years. “A lot of people think it’s a grandma’s disease, but it’s not. It could strike anyone at any time.”
Topics for the “A Different Shade of Pink” event will include treatment options, clinical trials, genetic testing, the role of exercise, survivorship services and more. The event will begin with a social hour and food with the program starting at 6 p.m.
“One of the important roles of an academic medical center like UTMC is education and outreach,” said Dr. Iman Mohamed, associate dean of medical school admissions and chief of the UTMC Division of Hematology and Oncology. “We invite anyone impacted by triple negative breast cancer or those curious about the disease to attend this event and learn more about it.”
“I hope people walk out of this feeling more informed of this disease and the treatments available,” Paskvan said.
To hear Paskvan’s story, read her blog at mlsspaskvan.blogspot.com. Paskvan also is raising money for triple negative breast cancer; donations can be made at tnbcday2014.kintera.org/tnbcsistersunite_melissa.
To RSVP to the “A Different Shade of Pink” event, email Janelle Tipton, oncology clinical nurse specialist, at Janelle.Tipton@utoledo.edu by Friday, Feb. 28.
UT News » Blog Archive » Public invited to learn about aggressive subtype of breast cancer; RSVP by Feb. 28

Total Pageviews



"click image to link"